

Diese Meldung kann unter <http://www.presseportal.de/meldung/1542662/> abgerufen werden.

# epigenomics

EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act):

Epigenomics AG: Licensing Partner Quest Diagnostics Introduces Colorectal Cancer Blood Test in the U.S.

11.01.2010 - 16:54 Uhr, Epigenomics AG

-----  
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro  
adhoc with the aim of a Europe-wide distribution. The issuer is solely  
responsible for the content of this announcement.  
-----

New Products/Molecular diagnostics

11.01.2010

Berlin, January 11, 2010 - Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, informs that Quest Diagnostics Incorporated, Madison, NJ, U.S.A., today introduced its laboratory developed blood test for aiding the detection of colorectal cancer in the United States. The test was independently developed by Quest Diagnostics based on Epigenomics' proprietary DNA methylation biomarker Septin9 and certain proprietary technologies that were licensed to Quest Diagnostics in 2008. The introduction follows the successful completion of the clinical validation of this laboratory developed test in November 2009 and the release of the test for offering to doctors and patients in December 2009.

Physicians in the United States may order the test through a Quest Diagnostics regional laboratory. With the introduction of this test, Epigenomics continues executing its dual business model of non-exclusive licensing and direct commercialization of its cancer molecular diagnostic biomarkers and products.

End of Ad hoc

Further Information

For further information please see today's press release by Quest Diagnostics at <http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irol-news>

Epigenomics legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

end of announcement euro adhoc

-----  
Further inquiry note:

Epigenomics AG  
Dr. Achim Plum  
Sen. VP Corporate Development  
Tel: +49 30 24345 368  
[achim.plum@epigenomics.com](mailto:achim.plum@epigenomics.com)

Branche: Biotechnology  
ISIN: DE000A0BVT96  
WKN: A0BVT9  
Index: Prime All Share, Technology All Share  
Börsen: Frankfurt / regulated dealing/prime standard  
Berlin / free trade  
Hamburg / free trade  
Stuttgart / free trade  
Düsseldorf / free trade  
München / free trade

Original text: Epigenomics AG  
ISIN: DE000A0BVT96  
Digitale Pressemappe: <http://www.presseportal.de/pm/38683/>  
Pressemappe via RSS: [http://presseportal.de/rss/pm\\_38683.rss2](http://presseportal.de/rss/pm_38683.rss2)